Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Pimavanserin · Nuplazid, ACP-103

Small molecule · Antagonist of serotonin 5-HT2A receptor (HTR2A) · developed by Acadia Pharms

Approved FDA, Apr 2016

ACAD Developer

5 Registered trials

What is Pimavanserin?

Pimavanserin is a small-molecule antagonist of serotonin 5-HT2A receptors and, to a lesser extent, 5-HT2C receptors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Nuplazid, ACP-103, Nuzplazid
Drug type: Small molecule
Targets: serotonin 5-HT2A receptor (HTR2A), serotonin 5-HT2C receptor (HTR2C) (secondary target)
Mechanism: Antagonist of serotonin 5-HT2A receptor (HTR2A)
Therapy area: Neurology, Psychiatry
Developer: Acadia Pharms Inc (ACAD)
FDA status: Approved as Nuplazid (April 29, 2016), NDA207318 · FDA label
UNII: JZ963P0DIK

✅ FDA-approved uses

Hallucinations and delusions associated with Parkinson's disease psychosis

From the indications section of the FDA label (version of Jun 18, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01174004	Phase 3	Parkinson's Disease Psychosis	Completed	ACAD
NCT00550238	Phase 3	Parkinson's Disease Psychosis	Completed	ACAD
NCT05999240	Phase 2	Autism Spectrum Disorder	Recruiting	ACAD
NCT03994965	Phase 2	Schizophrenia	Withdrawn	ACAD
NCT03947216	Phase 2	Parkinson Disease	Completed	ACAD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autism Spectrum DisorderParkinson DiseaseParkinson's Disease PsychosisPsychosisSchizophrenia

Other drugs acting on HTR2A

Aripiprazole Lauroxil FDA approved Asenapine FDA approved Iloperidone FDA approved Milsaperidone FDA approved Psilocybin Phase 3

More from Acadia Pharms

ACP-044 Phase 2 ACP-104 Phase 2 ACP-204 Phase 3 ACP-211 Phase 2 Carbetocin Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACAD page.

Follow ACAD, the company behind Pimavanserin

See ACAD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACAD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z